Clinical trial
Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer
NCT00041652 · Gilead Sciences, Industry · Completed
Key facts
| NCT number | NCT00041652 |
|---|---|
| Title | Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer |
| Official title | A Phase I/II Clinical Trial of Immunotherapy With Humanized MN-14 IgG in Recurrent, Metastatic, Unresectable Colorectal and Breast Carcinomas |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer, Colon Cancer, Rectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Breast Cancer, Breast Neoplasms |
| Intervention type | Drug |
| Interventions | hMN14 (labetuzumab) |
| Enrollment | 30 |
| Start date | Feb 1, 2000 |
| Completion | Jun 1, 2003 |
| First posted | Jul 15, 2002 |
| Last update posted | Aug 19, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: